41 results on '"Mealing, S"'
Search Results
2. EVALUATING THE COST-EFFECTIVENESS OF FIRST-LINE CRYOBALLOON ABLATION VERSUS ANTIARRHYTHMIC DRUG THERAPY FOR THE TREATMENT OF PAROXYSMAL ATRIAL FIBRILLATION FROM A CANADIAN HEALTHCARE PAYER PERSPECTIVE
3. EVALUATING THE COST-EFFECTIVENESS OF FIRST-LINE CRYOBALLOON ABLATION VERSUS ANTIARRHYTHMIC DRUG THERAPY FOR THE TREATMENT OF PAROXYSMAL ATRIAL FIBRILLATION FROM A CANADIAN HEALTHCARE PAYER PERSPECTIVE
4. PCR261 Elicitation of Health Utilities Online in Patients With Spinal Muscular Atrophy
5. EE362 Evaluating the Cost-Effectiveness of Refluxstop as a Treatment for Refractory Gastroesophageal Reflux Disease (GORD)
6. EE222 Evaluating the Budget Impact on the Health Care System in England and Wales of RefluxStop as a Treatment for Refractory Gastroesophageal Reflux Disease (GORD)
7. Abstract No. 556 Cost-effectiveness of radioembolization with Y-90 glass microspheres versus transarterial chemotherapies in the treatment of intermediate stage hepatocellular carcinoma: a U.S. hospital perspective
8. PSY11 Systematic Literature Review to Assess Overall Costs and Societal Impacts of Atopic Dermatitis in Europe
9. PRO67 The Use of Vignettes to Derive Health Utilities for Spinal Muscular Atrophy Type I (SMA-I)
10. PSU3 A Framework for Evaluating the Health and Cost Implications of Antimicrobial Resistance in the Context of Surgical Procedures
11. PIH11 ECONOMIC EVALUATION OF OSPEMIFENE FOR THE TREATMENT OF VULVOVAGINAL ATROPHY IN THE UNITED KINGDOM
12. PCV51 COST-EFFECTIVENESS OF RIVAROXABAN IN THE TREATMENT OF PATIENTS WITH CHRONIC CAD OR PAD IN THE UK
13. PRS27 - Cost-Effectiveness of a Single Inhaler Triple Therapy vs a Dual Inhaled Corticosteroid Plus Long-Acting Beta Agonist (ICS/LABA) for Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United Kingdom (UK)
14. PRM80 - A Novel Modelling Approach to Evaluate the Cost-Effectiveness of Chronic Obstructive Pulmonary Disease (COPD) Interventions
15. PMD107 - Predicting Quality Adjusted Life Years Using St. George Respiratory Results In Patients With Severe Emphysema Treated with Endobronchial Coils In Addition To Standard of Care Compared To Standard of Care Alone
16. 769 - Novel therapies in chronic lymphocytic leukaemia (CLL): quantifying the impact on patient relevant outcome measures
17. PRM108 - Multithreading: Turbocharged Cost-Effectiveness Analyses in Microsoft Excel
18. PRM26 - Synthesis of Binary Outcome Data on the Log-Odds and Absolute Risk Scales – A Case Study in Chronic Hepatitis C
19. PSY44 - THE COST EFFECTIVENESS OF AFAMELANOTIDE FOR THE TREATMENT OF ERYTHROPOIETIC PROTOPORHYRIA
20. PMD89 - Long-Term Cost-Effectiveness of Transanal Irrigation In Patients With Neurogenic Bowel Dysfunction Who Have Failed Standard Bowel Care
21. PND10 - Comparison of clinical effectiveness of Treatments for Pseudobulbar affect (Pba) €“ results from a systematic review
22. PSS22 - Cost-effectiveness of Ikervis® in severe dry Eye disease in the UK
23. PND35 - Nuedexta for the Treatment of Pseudobulbar Affect: Estimating the Financial Impact to the Scottish NHS
24. PUK5 - The Economic And Humanistic Burden Of Treatment Alternatives For The Management Of Chronic Urinary Retention In Adult Spinal Cord Injured Individuals
25. Les modélisations médico-économiques doivent-elles prendre en compte la charge virale à l’état basal dans l’efficacité relative des traitements de l’hépatite chronique B (HCB) chez le patient HBeAg positif naïf de traitement ? Résultats ajustés et non ajustés d’une méta-analyse en réseau
26. PCV77 - A cost-effectiveness analysis of transcatheter aortic-valve implantation (TAVI) compared to medical management for severe aortic stenosis in Colombia
27. PGI3 - Do you need to account for baseline viral load when assessing the relative efficacy of interventions for treatment naïve hbeag positive chronic hepatitis b (chb) patients? results from unadjusted and adjusted network meta-analyses (nma)
28. PSY37 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 600/800mg Daily as Therapy for Imatinib Failing Chronic Myeloid Leukemia (CML)
29. PSY38 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 400mg Daily in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML)
30. PCN189 The Use of Parametric Survival Analysis to Predict Progression Free and Overall Survival of Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients
31. PGI3 Current Treatments for Chronic Hepatitis B: A Systematic Review
32. PMD70 A Review of the Geographic Variations in the Implant Rate of Transcatheter Aortic Valves in 14 European Countries
33. PMD27 Cost-Effectiveness Analysis of Cardiac Resynchronization Therapy in Patients with Asymptomatic to Mild Heart Failure Based on the European Cohort of the reverse Study from the Spanish Health System Perspective
34. PCV87 USING VALUE OF INFORMATION ANALYSIS IN COMBINATION WITH AN EARLY STAGE MODEL OF COREVALVE FOR SEVERE AORTIC STENOSIS TO INFORM FUTURE RESEARCH NEEDS
35. PCV71 IS COREVALVE A COST-EFFECTIVE TREATMENT FOR PATIENTS WITH SEVERE AORTIC STENOSIS WHO SATISY ALL THE CRITERIA FOR CONVENTIONAL AORTIC VALVE REPLACEMENT?
36. PCV33 ESTIMATING THE FINANCIAL IMPLICATIONS TO THE UK NHS OF INTRODUCING COREVALVE ALONGSIDE MEDICAL MANAGEMENT FOR THE TREATMENT OF SEVERE AORTIC STENOSIS
37. PMC18 CONCEPTUALISING DISEASE: BUILDING UNIFYING MODELS TO SUPPORT THE DEVELOPMENT OF PROS AND COST-EFFECTIVENESS ANALYSES. A CASE STUDY IN ALZHEIMER—S DISEASE (AD)
38. PCN173 - Cost-Effectiveness Of Idelalisib Plus Rituximab In Chronic Lymphocytic Leukaemia
39. PCN141 - The Cost Effectiveness Of Idelalisib In Chronic Lymphocytic Leukaemia In England And Wales
40. PSS37 - Cost-Effectiveness of Ikervis® In Severe Dry Eye Disease In The Uk [Update]
41. PRM21 - Time Ratios Or Hazard Ratios: Accelerating Toward A New Approach?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.